JP2023506834A5 - - Google Patents
Info
- Publication number
- JP2023506834A5 JP2023506834A5 JP2022536639A JP2022536639A JP2023506834A5 JP 2023506834 A5 JP2023506834 A5 JP 2023506834A5 JP 2022536639 A JP2022536639 A JP 2022536639A JP 2022536639 A JP2022536639 A JP 2022536639A JP 2023506834 A5 JP2023506834 A5 JP 2023506834A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding site
- seq
- amino acid
- multispecific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962946932P | 2019-12-11 | 2019-12-11 | |
| US62/946,932 | 2019-12-11 | ||
| PCT/US2020/064672 WO2021119531A1 (en) | 2019-12-11 | 2020-12-11 | Anti-serum albumin antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023506834A JP2023506834A (ja) | 2023-02-20 |
| JP2023506834A5 true JP2023506834A5 (https=) | 2023-12-18 |
| JP7734132B2 JP7734132B2 (ja) | 2025-09-04 |
Family
ID=76329090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022536639A Active JP7734132B2 (ja) | 2019-12-11 | 2020-12-11 | 抗血清アルブミン抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230032087A1 (https=) |
| EP (1) | EP4073114A4 (https=) |
| JP (1) | JP7734132B2 (https=) |
| CN (1) | CN115916816B (https=) |
| AU (1) | AU2020403153A1 (https=) |
| CA (1) | CA3161411A1 (https=) |
| IL (1) | IL293780A (https=) |
| WO (1) | WO2021119531A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL293725A (en) | 2019-12-11 | 2022-08-01 | Cullinan Oncology Inc | Anti-cd19 antibodies and multispecific binding proteins |
| US20250388663A1 (en) * | 2022-08-17 | 2025-12-25 | Institut National de la Santé et de la Recherche Médicale | Improved anti-albumin nanobodies and their uses |
| TW202448926A (zh) | 2023-02-17 | 2024-12-16 | 比利時商艾伯霖克斯公司 | 結合新生兒fc受體之多肽 |
| WO2025106915A1 (en) | 2023-11-17 | 2025-05-22 | Sail Biomedicines, Inc. | Circular polyribonucleotides encoding glucagon-like peptide 1 (glp-1) and uses thereof |
| WO2025201474A1 (zh) * | 2024-03-28 | 2025-10-02 | 诺纳生物（苏州）有限公司 | 血清白蛋白结合蛋白及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101128487B (zh) * | 2004-12-02 | 2012-10-10 | 杜门蒂斯有限公司 | 靶向血清白蛋白和glp-1或pyy的双特异性结构域抗体 |
| HRP20150175T1 (en) * | 2005-12-16 | 2015-03-27 | Amgen Research (Munich) Gmbh | Means and methods for the treatment of tumorous diseases |
| DK2211904T3 (en) * | 2007-10-19 | 2016-10-24 | Seattle Genetics Inc | Cd19-binding agents and uses thereof |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| PE20141522A1 (es) * | 2011-08-17 | 2014-11-17 | Glaxo Group Ltd | Proteinas y peptidos modificados |
| US9708412B2 (en) | 2015-05-21 | 2017-07-18 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| AU2016330807B2 (en) * | 2015-10-02 | 2023-08-10 | F. Hoffmann-La Roche Ag | Anti-human CD19 antibodies with high affinity |
| KR20180133442A (ko) * | 2016-04-13 | 2018-12-14 | 비비아 바이오테크 에스.엘. | 생체외 bite 활성화된 t 세포 |
| WO2019077062A1 (en) * | 2017-10-18 | 2019-04-25 | Vivia Biotech, S.L. | C-CELLS ACTIVATED BY BIT |
| JP7383704B2 (ja) * | 2018-06-07 | 2023-11-20 | カリナン オンコロジー インコーポレイテッド | 多重特異性結合タンパク質およびその使用方法 |
| US10815311B2 (en) * | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
-
2020
- 2020-12-11 IL IL293780A patent/IL293780A/en unknown
- 2020-12-11 CA CA3161411A patent/CA3161411A1/en active Pending
- 2020-12-11 US US17/785,011 patent/US20230032087A1/en active Pending
- 2020-12-11 WO PCT/US2020/064672 patent/WO2021119531A1/en not_active Ceased
- 2020-12-11 JP JP2022536639A patent/JP7734132B2/ja active Active
- 2020-12-11 EP EP20899790.8A patent/EP4073114A4/en active Pending
- 2020-12-11 CN CN202080096427.XA patent/CN115916816B/zh active Active
- 2020-12-11 AU AU2020403153A patent/AU2020403153A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023506834A5 (https=) | ||
| CN112955471B (zh) | Cd3抗体及其药物用途 | |
| JP2025111463A5 (https=) | ||
| JP2022177090A5 (https=) | ||
| JP2021534762A5 (https=) | ||
| JP2021508469A5 (https=) | ||
| CN112969476B (zh) | 多特异性蛋白分子 | |
| JP2024522360A5 (https=) | ||
| US12098203B2 (en) | Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA | |
| JP2024510098A5 (https=) | ||
| CN111417653A (zh) | Cd47抗原结合分子 | |
| JP2020525032A5 (https=) | ||
| JP2022533538A5 (https=) | ||
| JP2020515277A5 (https=) | ||
| JP2023506017A5 (https=) | ||
| JP7836033B2 (ja) | Ｇｐｒｃ５ｄ抗体及びその応用 | |
| JP2025038088A5 (https=) | ||
| JP2024540148A5 (https=) | ||
| JP2023545183A5 (https=) | ||
| JP2024516098A5 (https=) | ||
| JP2021512652A5 (https=) | ||
| CN111712521A (zh) | Cd38蛋白抗体及其应用 | |
| IL315960A (en) | Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof | |
| JP2025511135A5 (https=) | ||
| JP2024546763A5 (https=) |